

Mar Masia

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2336136/publications.pdf>

Version: 2024-02-01

173
papers

6,430
citations

93792

39
h-index

100535

70
g-index

193
all docs

193
docs citations

193
times ranked

8794
citing authors

#	ARTICLE	IF	CITATIONS
1	Use of generic antiretroviral drugs and single-tablet regimen de-simplification for the treatment of HIV infection in Spain. <i>AIDS Research and Human Retroviruses</i> , 2022, , .	0.5	1
2	Clinical Performance of a Standardized Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Interferon- γ Release Assay for Simple Detection of T-Cell Responses After Infection or Vaccination. <i>Clinical Infectious Diseases</i> , 2022, 75, e338-e346.	2.9	27
3	Atherogenicity of low-density lipoproteins after switching from a protease inhibitor to dolutegravir: a substudy of the NEAT022 study. <i>Journal of Antimicrobial Chemotherapy</i> , 2022, , .	1.3	1
4	Survival benefit of remdesivir in hospitalized COVID-19 patients with high SARS-CoV-2 viral loads and low-grade systemic inflammation. <i>Journal of Antimicrobial Chemotherapy</i> , 2022, 77, 2257-2264.	1.3	17
5	Robust long-term immunity to SARS-CoV-2 in patients recovered from severe COVID-19 after interleukin-6 blockade. <i>EBioMedicine</i> , 2022, 82, 104153.	2.7	8
6	Dyspnea and pleuritic chest pain during the COVID-19 pandemic. <i>Enfermedades Infecciosas Y MicrobiologÃa ClÃnica</i> , 2021, 39, 41-42.	0.3	3
7	Evaluation of the rapid antigen test Panbio COVID-19 in saliva and nasal swabs in a population-based point-of-care study. <i>Journal of Infection</i> , 2021, 82, 186-230.	1.7	56
8	Lack of detrimental effect of corticosteroids on antibody responses to SARS-CoV-2 and viral clearance in patients hospitalized with COVID-19. <i>Journal of Infection</i> , 2021, 82, 414-451.	1.7	10
9	Performance of Saliva Specimens for the Molecular Detection of SARS-CoV-2 in the Community Setting: Does Sample Collection Method Matter?. <i>Journal of Clinical Microbiology</i> , 2021, 59, .	1.8	21
10	Switching from boosted PIs to dolutegravir decreases soluble CD14 and adiponectin in high cardiovascular risk people living with HIV. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 2380-2393.	1.3	13
11	Incidence of delayed asymptomatic COVID-19 recurrences in a 6-month longitudinal study. <i>Journal of Infection</i> , 2021, 82, 276-316.	1.7	5
12	Antibody Response to SARS-CoV-2 is Associated with Long-term Clinical Outcome in Patients with COVID-19: a Longitudinal Study. <i>Journal of Clinical Immunology</i> , 2021, 41, 1490-1501.	2.0	95
13	Differences in epidemiology and mortality between men and women with HIV infection in the CoRIS cohort from 2004 to 2014. <i>Enfermedades Infecciosas Y Microbiologia Clinica (English Ed)</i> , 2021, 39, 372-382.	0.2	1
14	Durable antibody response one year after hospitalization for COVID-19: A longitudinal cohort study. <i>Journal of Autoimmunity</i> , 2021, 123, 102703.	3.0	37
15	Late reinfection with a different severe acute respiratory syndrome coronavirus-2 clade in a patient with refractory arterial hypertension: a case report. <i>Journal of Medical Case Reports</i> , 2021, 15, 454.	0.4	0
16	SARS-CoV-2 Seroconversion and Viral Clearance in Patients Hospitalized With COVID-19: Viral Load Predicts Antibody Response. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab005.	0.4	52
17	Diferencias epidemiolÃgicas y de mortalidad entre hombres y mujeres con infecciÃn por VIH en la cohorte CoRIS entre los aÃos 2004 y 2014. <i>Enfermedades Infecciosas Y MicrobiologÃa ClÃnica</i> , 2021, 39, 372-382.	0.3	5
18	Impact of the Addition of Baricitinib to Standard of Care Including Tocilizumab and Corticosteroids on Mortality and Safety in Severe COVID-19. <i>Frontiers in Medicine</i> , 2021, 8, 749657.	1.2	13

#	ARTICLE	IF	CITATIONS
19	Impact of an enhanced screening program on the detection of non-AIDS neoplasias in patients with human immunodeficiency virus infection. <i>Trials</i> , 2021, 22, 851.	0.7	6
20	Physicians'™ opinions on generic antiretroviral drugs and single-tablet regimen de-simplification for the treatment of HIV infection: a multicentre survey in Spain. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 466-472.	1.3	6
21	Infection With <i>Chlamydia trachomatis</i> Increases the Risk of High-grade Anal Intraepithelial Neoplasia in People Living With Human Immunodeficiency Virus. <i>Clinical Infectious Diseases</i> , 2020, 70, 2161-2167.	2.9	4
22	Latent and active tuberculosis infections in migrants and travellers: A retrospective analysis from the Spanish +REDIVI collaborative network. <i>Travel Medicine and Infectious Disease</i> , 2020, 36, 101460.	1.5	10
23	How well are we performing the initial assessment of HIV-positive patients? Results from a multicentre cohort in Spain. <i>HIV Medicine</i> , 2020, 21, 128-134.	1.0	0
24	Rectal and seminal HIV-1 RNA decay towards virological suppression in infected MSM initiating dolutegravir/abacavir/lamivudine. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 668-674.	1.3	8
25	Effects of first-line antiretroviral therapy on the CD4/CD8 ratio and CD8 cell counts in CoRIS: a prospective multicentre cohort study. <i>Lancet HIV</i> , 2020, 7, e565-e573.	2.1	42
26	Preemptive interleukin-6 blockade in patients with COVID-19. <i>Scientific Reports</i> , 2020, 10, 16826.	1.6	35
27	Predictive factors for cardiac conduction abnormalities with hydroxychloroquine-containing combinations for COVID-19. <i>International Journal of Antimicrobial Agents</i> , 2020, 56, 106142.	1.1	6
28	Effectiveness of the combination elvitegravir/cobicistat/tenofovir/emtricitabine (EVG/COB/TFV/FTC) plus darunavir among treatment-experienced patients in clinical practice: a multicentre cohort study. <i>AIDS Research and Therapy</i> , 2020, 17, 45.	0.7	1
29	Switching from boosted PIs to dolutegravir in HIV-infected patients with high cardiovascular risk: 48 week effects on subclinical cardiovascular disease. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 3334-3343.	1.3	5
30	Virological outcome among HIV infected patients transferred from pediatric care to adult units in Madrid, Spain (1997-2017). <i>Scientific Reports</i> , 2020, 10, 16891.	1.6	3
31	Impact of interleukin-6 blockade with tocilizumab on SARS-CoV-2 viral kinetics and antibody responses in patients with COVID-19: A prospective cohort study. <i>EBioMedicine</i> , 2020, 60, 102999.	2.7	71
32	Primary resistance to integrase strand transfer inhibitors in Spain using ultrasensitive HIV-1 genotyping. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 3517-3524.	1.3	6
33	COVID-19-associated encephalitis successfully treated with combination therapy. <i>Clinical Infection in Practice</i> , 2020, 7-8, 100053.	0.2	19
34	Long-Acting Injectable Cabotegravir + Rilpivirine for HIV Maintenance Therapy: Week 48 Pooled Analysis of Phase 3 ATLAS and FLAIR Trials. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2020, 85, 498-506.	0.9	78
35	Long-Acting Cabotegravir and Rilpivirine for Maintenance of HIV-1 Suppression. <i>New England Journal of Medicine</i> , 2020, 382, 1112-1123.	13.9	266
36	The algorithm used for the interpretation of doravirine transmitted drug resistance strongly influences clinical practice and guideline recommendations. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 1294-1300.	1.3	12

#	ARTICLE	IF	CITATIONS
37	Imported cysticercosis in Spain: A retrospective case series from the +REDIVI Collaborative Network. <i>Travel Medicine and Infectious Disease</i> , 2020, 37, 101683.	1.5	7
38	Immediate Versus Deferred Switching From a Boosted Protease Inhibitor-based Regimen to a Dolutegravir-based Regimen in Virologically Suppressed Patients With High Cardiovascular Risk or Age ≥50 Years: Final 96-Week Results of the NEAT022 Study. <i>Clinical Infectious Diseases</i> , 2019, 68, 597-606.	2.9	34
39	Evolving understanding of cardiovascular, cerebrovascular and peripheral arterial disease in people living with HIV and role of novel biomarkers. A study of the Spanish CoRIS cohort, 2004-2015. <i>PLoS ONE</i> , 2019, 14, e0215507.	1.1	11
40	Risk of cancer in HIV-infected patients in Spain, 2004-2015. The CoRIS cohort study. <i>Enfermedades Infecciosas Y Microbiología Clínica (English Ed)</i> , 2019, 37, 502-508.	0.2	4
41	Risk of HIV transmission through condomless sex in serodifferent gay couples with the HIV-positive partner taking suppressive antiretroviral therapy (PARTNER): final results of a multicentre, prospective, observational study. <i>Lancet, The</i> , 2019, 393, 2428-2438.	6.3	627
42	Contribution of Human Herpesvirus 8 and Herpes Simplex Type 2 to Progression of Carotid Intima-Media Thickness in People Living With HIV. <i>Open Forum Infectious Diseases</i> , 2019, 6, ofz041.	0.4	1
43	Riesgo de cáncer en personas con VIH en España, 2004-2015. Estudio de la cohorte CoRIS. <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2019, 37, 502-508.	0.3	12
44	Clinicoepidemiological characteristics of viral hepatitis in migrants and travellers of the +Redivi network. <i>Travel Medicine and Infectious Disease</i> , 2019, 29, 51-57.	1.5	6
45	Congenital HIV infection after failure of serological screening. Importance of implementing a second screening for HIV infection during the third trimester of pregnancy. <i>Enfermedades Infecciosas Y Microbiología Clínica (English Ed)</i> , 2019, 37, 619.	0.2	0
46	Short-term Increase in Risk of Overweight and Concomitant Systolic Blood Pressure Elevation in Treatment-Naïve Persons Starting INSTI-based Antiretroviral Therapy. <i>Open Forum Infectious Diseases</i> , 2019, 6, ofz491.	0.4	16
47	Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naïve adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials. <i>Lancet, The</i> , 2019, 393, 143-155.	6.3	265
48	Infección congénita por el VIH con cribado serológico gestacional negativo. Importancia de la implementación de la segunda prueba en el tercer trimestre de gestación. <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2019, 37, 618-619.	0.3	0
49	Evaluation of the Virclia [®] automated chemiluminescent immunoassay system for diagnosing pneumonia caused by <i>Mycoplasma pneumoniae</i> . <i>Journal of Clinical Laboratory Analysis</i> , 2018, 32, e22431.	0.9	4
50	Decreasing rates of acute myocardial infarction in people living with HIV: a nationwide cohort study in Spain, 2004-2015. <i>HIV Medicine</i> , 2018, 19, 491-496.	1.0	8
51	Sofosbuvir plus daclatasvir as an alternative for patients on haemodialysis with genotype 2 hepatitis C virus infection. <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2018, 36, 457.	0.3	1
52	High-grade anal intraepithelial neoplasia is associated with HIV-1 RNA rectal shedding in virologically suppressed MSM. <i>Aids</i> , 2018, 32, 1017-1024.	1.0	5
53	Executive summary of the consensus document on osteoporosis in HIV-infected individuals. <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2018, 36, 312-314.	0.3	7
54	Dalbavancin in the treatment of different gram-positive infections: a real-life experience. <i>International Journal of Antimicrobial Agents</i> , 2018, 51, 571-577.	1.1	125

#	ARTICLE	IF	CITATIONS
55	Interferon-free therapy for treating hepatitis C virus in difficult-to-treat HIV-coinfected patients. <i>Aids</i> , 2018, 32, 337-346.	1.0	6
56	Developments in early diagnosis and therapy of HIV infection in newborns. <i>Expert Opinion on Pharmacotherapy</i> , 2018, 19, 13-25.	0.9	10
57	Barriers to health care services for migrants living with HIV in Spain. <i>European Journal of Public Health</i> , 2018, 28, 451-457.	0.1	23
58	A âœlipo-touristâœ with chronic cutaneous lesions after surgery in Ecuador: A diagnostic challenge. <i>Travel Medicine and Infectious Disease</i> , 2018, 25, 77-78.	1.5	7
59	Role of HIV in the desire of procreation and motherhood in women living with HIV in Spain: a qualitative approach. <i>BMC Women's Health</i> , 2018, 18, 24.	0.8	3
60	Contribution of Oxidative Stress to Non-AIDS Events in HIV-Infected Patients. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2017, 75, e36-e44.	0.9	10
61	Severe skull base osteomyelitis caused by <i>Pseudomonas aeruginosa</i> with successful outcome after prolonged outpatient therapy with continuous infusion of ceftazidime and oral ciprofloxacin: a case report. <i>Journal of Medical Case Reports</i> , 2017, 11, 48.	0.4	13
62	Switching from a ritonavir-boosted protease inhibitor to a dolutegravir-based regimen for maintenance of HIV viral suppression in patients with high cardiovascular risk. <i>Aids</i> , 2017, 31, 2503-2514.	1.0	65
63	Screening for precancerous anal lesions with P16/Ki67 immunostaining in HIV-infected MSM. <i>PLoS ONE</i> , 2017, 12, e0188851.	1.1	15
64	Procalcitonin for selecting the antibiotic regimen in outpatients with low-risk community-acquired pneumonia using a rapid point-of-care testing: A single-arm clinical trial. <i>PLoS ONE</i> , 2017, 12, e0175634.	1.1	8
65	Prediction of long-term outcomes of HIV-infected patients developing non-AIDS events using a multistate approach. <i>PLoS ONE</i> , 2017, 12, e0184329.	1.1	6
66	Statins in HIV-Infected Patients: Potential Beneficial Effects and Clinical Use. <i>AIDS Reviews</i> , 2017, 19, 59-71.	0.5	12
67	Incidence and clearance of anal high-risk human papillomavirus in HIV-positive men who have sex with men. <i>Aids</i> , 2016, 30, 37-44.	1.0	46
68	Comparative Impact of Suppressive Antiretroviral Regimens on the CD4/CD8 T-Cell Ratio. <i>Medicine (United States)</i> , 2016, 95, e3108.	0.4	24
69	Relationship between plasma bilirubin level and oxidative stress markers in <sc>HIV</sc>-infected patients on atazanavirâœ vs</i>. efavirenzâœ-based antiretroviral therapy. <i>HIV Medicine</i> , 2016, 17, 653-661.	1.0	20
70	Withdrawing inactive NRTIs in HIV-1 subjects with suppressed viraemia: a randomized trial. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 1346-1351.	1.3	3
71	The CD4/CD8 Ratio is Inversely Associated with Carotid Intima-Media Thickness Progression in Human Immunodeficiency Virus-Infected Patients on Antiretroviral Treatment. <i>AIDS Research and Human Retroviruses</i> , 2016, 32, 648-653.	0.5	26
72	Oxidative Stress Predicts All-Cause Mortality in HIV-Infected Patients. <i>PLoS ONE</i> , 2016, 11, e0153456.	1.1	40

#	ARTICLE	IF	CITATIONS
73	Vitamin D deficiency: One more piece of the puzzle of cardiovascular risk in human immunodeficiency virus-infected patients?. <i>Medicina Clínica (English Edition)</i> , 2015, 144, 118-120.	0.1	0
74	Differential Body Composition Effects of Protease Inhibitors Recommended for Initial Treatment of HIV Infection: A Randomized Clinical Trial. <i>Clinical Infectious Diseases</i> , 2015, 60, 811-820.	2.9	26
75	Cardiovascular risk factors and lifetime risk estimation in HIV-infected patients under antiretroviral treatment in Spain. <i>HIV Clinical Trials</i> , 2015, 16, 57-65.	2.0	18
76	First Human Systemic Infection Caused by Spiroplasma. <i>Journal of Clinical Microbiology</i> , 2015, 53, 719-721.	1.8	29
77	Safety, efficacy and indications of prescription of maraviroc in clinical practice: Factors associated with clinical outcomes. <i>Antiviral Research</i> , 2015, 120, 79-84.	1.9	16
78	Virological failure to raltegravir in Spain: incidence, prevalence and clinical consequences. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 3087-3095.	1.3	13
79	Relevant Gender Differences in Epidemiological Profile, Exposure to First Antiretroviral Regimen and Survival in the Spanish Aids Research Network Cohort. <i>Antiviral Therapy</i> , 2014, 19, 375-385.	0.6	9
80	Clinically Relevant Transmitted Drug Resistance to First Line Antiretroviral Drugs and Implications for Recommendations. <i>PLoS ONE</i> , 2014, 9, e90710.	1.1	17
81	Incidence of Hepatitis C Virus (HCV) in a Multicenter Cohort of HIV-Positive Patients in Spain 2004-2011: Increasing Rates of HCV Diagnosis but Not of HCV Seroconversions. <i>PLoS ONE</i> , 2014, 9, e116226.	1.1	19
82	Recurrence of active tuberculosis following resumption of anti-TNF- α therapy in a patient with Crohn's disease [Correspondence]. <i>International Journal of Tuberculosis and Lung Disease</i> , 2014, 18, 249-250.	0.6	8
83	Early lipid changes with atazanavir/ritonavir or darunavir/ritonavir. <i>HIV Medicine</i> , 2014, 15, 330-338.	1.0	25
84	Compliance with national guidelines for HIV treatment and its association with mortality and treatment outcome: a study in a Spanish cohort. <i>HIV Medicine</i> , 2014, 15, 86-97.	1.0	12
85	X4 tropic viruses are on the rise in recent HIV-1 seroconverters in Spain. <i>Aids</i> , 2014, 28, 1603-1609.	1.0	14
86	Risk of clinically significant depression in HIV-infected patients: effect of antiretroviral drugs. <i>HIV Medicine</i> , 2014, 15, 213-223.	1.0	30
87	Long-term effects of an intensive intervention in HIV-infected patients with moderate-high atherosclerotic cardiovascular risk. <i>Journal of Antimicrobial Chemotherapy</i> , 2014, 69, 3051-3056.	1.3	8
88	Reproductive desire in women with HIV infection in Spain, associated factors and motivations: a mixed-method study. <i>BMC Pregnancy and Childbirth</i> , 2014, 14, 194.	0.9	17
89	Anal tuberculosis complicating anti-TNF α therapy. <i>BMJ Case Reports</i> , 2014, 2014, bcr2014206976-bcr2014206976.	0.2	5
90	Coinfection with Human Herpesvirus 8 Is Associated with Persistent Inflammation and Immune Activation in Virologically Suppressed HIV-Infected Patients. <i>PLoS ONE</i> , 2014, 9, e105442.	1.1	21

#	ARTICLE	IF	CITATIONS
91	Persistence of Novel First-Line Antiretroviral Regimes in a Cohort of HIV-Positive Subjects, Coris 2008–2010. <i>Antiviral Therapy</i> , 2013, 18, 161-170.	0.6	14
92	Short-Term and Long-Term Clinical and Immunological Consequences of Stopping Antiretroviral Therapy in HIV-Infected Patients with Preserved Immune Function. <i>Antiviral Therapy</i> , 2013, 18, 125-130.	0.6	17
93	Incidence and risk factors of AIDS-defining cancers in a cohort of HIV-positive adults: Importance of the definition of incident cases. <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2013, 31, 304-312.	0.3	9
94	All-cause mortality in the cohorts of the Spanish AIDS Research Network (RIS) compared with the general population: 1997–2010. <i>BMC Infectious Diseases</i> , 2013, 13, 382.	1.3	18
95	Negative effect of immunosuppressive therapy in the performance of the QuantiFERON Gold In-Tube test in patients with immune-mediated inflammatory diseases. <i>Clinical and Experimental Medicine</i> , 2013, 13, 177-186.	1.9	27
96	Endothelial function in HIV-infected patients switching from a boosted protease inhibitor-based regimen to raltegravir: a substudy of the SPIRAL study. <i>Journal of Antimicrobial Chemotherapy</i> , 2013, 68, 409-413.	1.3	19
97	What Drives the Number of High-Risk Human Papillomavirus Types in the Anal Canal in HIV-Positive Men Who Have Sex With Men?. <i>Journal of Infectious Diseases</i> , 2013, 207, 1235-1241.	1.9	33
98	Risk, predictors, and mortality associated with non-AIDS events in newly diagnosed HIV-infected patients. <i>Aids</i> , 2013, 27, 181-189.	1.0	53
99	Inequalities in HIV disease management and progression in migrants from Latin America and sub-Saharan Africa living in Spain. <i>HIV Medicine</i> , 2013, 14, 273-283.	1.0	39
100	Anal Human Papillomavirus Genotype Distribution in HIV-Infected Men Who Have Sex with Men by Geographical Origin, Age, and Cytological Status in a Spanish Cohort. <i>Journal of Clinical Microbiology</i> , 2013, 51, 3512-3520.	1.8	46
101	Human Infection with <i>Rickettsia sibirica mongolitimonae</i> , Spain, 2007–2011. <i>Emerging Infectious Diseases</i> , 2013, 19, 267-269.	2.0	40
102	Estimating the Burden of Pneumococcal Pneumonia among Adults: A Systematic Review and Meta-Analysis of Diagnostic Techniques. <i>PLoS ONE</i> , 2013, 8, e60273.	1.1	329
103	Increased Carotid Intima-Media Thickness Associated with Antibody Responses to Varicella-Zoster Virus and Cytomegalovirus in HIV-Infected Patients. <i>PLoS ONE</i> , 2013, 8, e64327.	1.1	22
104	Educational Gradient in HIV Diagnosis Delay, Mortality, Antiretroviral Treatment Initiation and Response in a Country with Universal Health Care. <i>Antiviral Therapy</i> , 2012, 17, 1-8.	0.6	43
105	Idiopathic ileocolitis with perforation associated with HIV infection: thalidomide treatment. <i>International Journal of STD and AIDS</i> , 2012, 23, 830-832.	0.5	1
106	Heterogeneity in outcomes of treated HIV-positive patients in Europe and North America: relation with patient and cohort characteristics. <i>International Journal of Epidemiology</i> , 2012, 41, 1807-1820.	0.9	34
107	Impact of Antiretroviral Therapy on Tuberculosis Incidence Among HIV-Positive Patients in High-Income Countries. <i>Clinical Infectious Diseases</i> , 2012, 54, 1364-1372.	2.9	58
108	Short Communication: Early Changes in Parathyroid Hormone Concentrations in HIV-Infected Patients Initiating Antiretroviral Therapy with Tenofovir. <i>AIDS Research and Human Retroviruses</i> , 2012, 28, 242-246.	0.5	64

#	ARTICLE	IF	CITATIONS
109	Most HIV Type 1 Non-B Infections in the Spanish Cohort of Antiretroviral Treatment-NaÄve HIV-Infected Patients (CoRIS) Are Due to Recombinant Viruses. <i>Journal of Clinical Microbiology</i> , 2012, 50, 407-413.	1.8	41
110	Evolution of HIV-1 genotype in plasma RNA and peripheral blood mononuclear cells proviral DNA after interruption and resumption of antiretroviral therapy. <i>Antiviral Therapy</i> , 2012, 17, 597.	0.6	0
111	Differences in the causes of death of HIV-positive patients in a cohort study by data sources and coding algorithms. <i>Aids</i> , 2012, 26, 1829-1834.	1.0	27
112	Changes in cardiovascular biomarkers in HIV-infected patients switching from ritonavir-boosted protease inhibitors to raltegravir. <i>Aids</i> , 2012, 26, 2315-2326.	1.0	104
113	Analysis of transmitted drug resistance in Spain in the years 2007Ä2010 documents a decline in mutations to the non-nucleoside drug class. <i>Clinical Microbiology and Infection</i> , 2012, 18, E485-E490.	2.8	26
114	Contribution of Interferon gamma release assays testing to the diagnosis of latent tuberculosis infection in HIV-infected patients: A comparison of QuantiFERON-TB Gold In Tube, T-SPOT.TB and tuberculin skin test. <i>BMC Infectious Diseases</i> , 2012, 12, 169.	1.3	46
115	The effect of efavirenz versus nevirapine-containing regimens on immunologic, virologic and clinical outcomes in a prospective observational study. <i>Aids</i> , 2012, 26, 1691-1705.	1.0	31
116	Predictors of Pneumococcal Co-infection for Patients with Pandemic (H1N1) 2009 Influenza. <i>Emerging Infectious Diseases</i> , 2011, 17, 1475-8.	2.0	8
117	A Highly Sensitive and Specific Model for Predicting HIV-1 Tropism in Treatment-Experienced Patients Combining Interpretation of V3 Loop Sequences and Clinical Parameters. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2011, 56, 51-58.	0.9	12
118	Evolution of HIV-1 genotype in plasma RNA and peripheral blood mononuclear cells proviral DNA after interruption and resumption of antiretroviral therapy. <i>Antiviral Therapy</i> , 2011, 17, 577-583.	0.6	7
119	Seroprevalence of <i>Toxoplasma gondii</i> infection among immigrant and native pregnant women in Eastern Spain. <i>Parasitology Research</i> , 2011, 109, 1447-1452.	0.6	41
120	Evaluation of endothelial function and subclinical atherosclerosis in association with hepatitis C virus in HIV-infected patients: a cross-sectional study. <i>BMC Infectious Diseases</i> , 2011, 11, 265.	1.3	33
121	Early changes in inflammatory and pro-thrombotic biomarkers in patients initiating antiretroviral therapy with abacavir or tenofovir. <i>BMC Infectious Diseases</i> , 2011, 11, 40.	1.3	32
122	Treatment for hepatitis C virus with pegylated interferon-Ä plus ribavirin induces anti-atherogenic effects on cardiovascular risk biomarkers in HIV-infected and -uninfected patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2011, 66, 1861-1868.	1.3	17
123	The role of HIV and antiretroviral therapy in bone disease. <i>AIDS Reviews</i> , 2011, 13, 109-18.	0.5	42
124	Endothelial function is impaired in HIV-infected patients with lipodystrophy. <i>Antiviral Therapy</i> , 2010, 15, 101-110.	0.6	37
125	Severe acute renal failure associated with rhabdomyolysis during treatment with raltegravir. Äcall for caution. <i>Journal of Infection</i> , 2010, 61, 189-190.	1.7	35
126	Diagnostic accuracy of sTREM-1 to identify infection in critically ill patients with systemic inflammatory response syndrome. <i>Clinical Biochemistry</i> , 2010, 43, 720-724.	0.8	38

#	ARTICLE	IF	CITATIONS
127	Clinical evaluation of rapid point-of-care testing for detection of novel influenza A (H1N1) virus in a population-based study in Spain. <i>Clinical Microbiology and Infection</i> , 2010, 16, 1358-1361.	2.8	33
128	Performance of Genotypic Algorithms for Predicting HIV-1 Tropism Measured against the Enhanced-Sensitivity Trofile Coreceptor Tropism Assay. <i>Journal of Clinical Microbiology</i> , 2010, 48, 4135-4139.	1.8	26
129	Different Lineages of Chikungunya Virus in Equatorial Guinea in 2002 and 2006. <i>American Journal of Tropical Medicine and Hygiene</i> , 2010, 82, 505-507.	0.6	19
130	Comparison of Combined Nose-Throat Swabs with Nasopharyngeal Aspirates for Detection of Pandemic Influenza A/H1N1 2009 Virus by Real-Time Reverse Transcriptase PCR. <i>Journal of Clinical Microbiology</i> , 2010, 48, 3492-3495.	1.8	40
131	<i>Listeria monocytogenes</i> infection in patients with inflammatory bowel diseases receiving anti-tumor necrosis factor therapy. <i>Revista Espanola De Enfermedades Digestivas</i> , 2010, 102, 614-6.	0.1	15
132	A pilot randomized trial comparing an intensive versus a standard intervention in stable HIV-infected patients with moderate-high cardiovascular risk. <i>Journal of Antimicrobial Chemotherapy</i> , 2009, 64, 589-598.	1.3	15
133	A bibliometric overview of infectious diseases research in European countries (2002-2007). <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2009, 28, 713-716.	1.3	24
134	Considerations on ankle-brachial index interpretation in HIV-infected patients. <i>HIV Medicine</i> , 2009, 10, 395-395.	1.0	1
135	Spanish Scientific Research Output on Tuberculosis Indexed in MEDLINE, 1997-2006. <i>Archivos De Bronconeumologia</i> , 2009, 45, 271-278.	0.4	10
136	Limited efficacy of a nonrestricted intervention on antimicrobial prescription of commonly used antibiotics in the hospital setting: results of a randomized controlled trial. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2008, 27, 597-605.	1.3	16
137	Improving Outcomes of Elderly Patients with Community-Acquired Pneumonia. <i>Drugs and Aging</i> , 2008, 25, 585-610.	1.3	23
138	Low Prevalence of Peripheral Arterial Disease in HIV-Infected Patients With Multiple Cardiovascular Risk Factors. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2008, 47, 126-127.	0.9	25
139	High-Density Lipoprotein Cholesterol in HIV-Infected Patients: Evidence for an Association with HIV-1 Viral Load, Antiretroviral Therapy Status, and Regimen Composition. <i>AIDS Patient Care and STDs</i> , 2008, 22, 569-575.	1.1	58
140	Relationship between ankle-brachial index and carotid intima-media thickness in HIV-infected patients. <i>Aids</i> , 2008, 22, 1369-1371.	1.0	26
141	Patients Characteristics and Clinical Implications of Suboptimal CD4 T-Cell Gains After 1 Year of Successful Antiretroviral Therapy. <i>Current HIV Research</i> , 2008, 6, 100-107.	0.2	66
142	Midregional Pro-A-Type Natriuretic Peptide and Carboxy-Terminal Provasopressin May Predict Prognosis in Community-Acquired Pneumonia. <i>Clinical Chemistry</i> , 2007, 53, 2193-2201.	1.5	51
143	Ultrasonography and Anthropometry for Measuring Regional Body Fat in HIV-Infected Patients. <i>Current HIV Research</i> , 2007, 5, 459-466.	0.2	12
144	Influence of Antiretroviral Therapy on Oxidative Stress and Cardiovascular Risk: A Prospective Cross-Sectional Study in HIV-Infected Patients. <i>Clinical Therapeutics</i> , 2007, 29, 1448-1455.	1.1	71

#	ARTICLE	IF	CITATIONS
145	The role of C-reactive protein as a marker for cardiovascular risk associated with antiretroviral therapy in HIV-infected patients. <i>Atherosclerosis</i> , 2007, 195, 167-171.	0.4	52
146	Fatal infection due to larval cysts of cestodes (neurocysticercosis and hydatid disease) in human immunodeficiency virus (HIV) infected patients in Spain: Report of two cases. <i>Scandinavian Journal of Infectious Diseases</i> , 2007, 39, 719-723.	1.5	28
147	Clinical characterisation of pneumonia caused by atypical pathogens combining classic and novel predictors. <i>Clinical Microbiology and Infection</i> , 2007, 13, 153-161.	2.8	30
148	Occult lymphadenopathic Kaposi's sarcoma associated with severe pulmonary hypertension: A clinical hint about the potential role of HHV-8 in HIV-related pulmonary hypertension?. <i>Journal of Clinical Virology</i> , 2006, 37, 79-82.	1.6	22
149	Clinical Outcome of HIV-Infected Patients with Sustained Virologic Response to Antiretroviral Therapy: Long-Term Follow-Up of a Multicenter Cohort. <i>PLoS ONE</i> , 2006, 1, e89.	1.1	42
150	Osteonecrosis in Patients Infected With HIV. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2006, 42, 286-292.	0.9	49
151	Techniques for measuring regional body fat: computed tomography may be suitable for evaluation of facial lipoatrophy. <i>Aids</i> , 2006, 20, 2237.	1.0	2
152	The influence of age and gender on the population-based incidence of community-acquired pneumonia caused by different microbial pathogens. <i>Journal of Infection</i> , 2006, 53, 166-174.	1.7	179
153	Usefulness of Procalcitonin Levels in Community-Acquired Pneumonia According to the Patients Outcome Research Team Pneumonia Severity Index. <i>Chest</i> , 2005, 128, 2223-2229.	0.4	171
154	Unexpected improvement of sexual dysfunction during atazanavir therapy. <i>Aids</i> , 2005, 19, 1440-1441.	1.0	7
155	Epidemiology of community-acquired pneumonia in adult patients at the dawn of the 21st century: a prospective study on the Mediterranean coast of Spain. <i>Clinical Microbiology and Infection</i> , 2005, 11, 788-800.	2.8	77
156	Pulmonary mycetoma caused by an atypical isolate of <i>Paecilomyces</i> species in an immunocompetent individual: case report and literature review of <i>Paecilomyces</i> lung infections. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2005, 24, 607-611.	1.3	24
157	Community-acquired pneumonia of mixed etiology: prevalence, clinical characteristics, and outcome. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2005, 24, 377-383.	1.3	50
158	Lack of Efficacy of Voriconazole Therapy in 2 Patients with Pulmonary Fungus Balls. <i>Clinical Infectious Diseases</i> , 2005, 40, 1706-1707.	2.9	4
159	Low Frequency of Renal Function Impairment During One-Year of Therapy with Tenofovir-Containing Regimens in the Real-World: A Case-Control Study. <i>AIDS Patient Care and STDs</i> , 2005, 19, 421-424.	1.1	41
160	Prediction of Neuropsychiatric Adverse Events Associated with Long-Term Efavirenz Therapy, Using Plasma Drug Level Monitoring. <i>Clinical Infectious Diseases</i> , 2005, 41, 1648-1653.	2.9	202
161	Geography of medical publications. An overview of HIV/AIDS research in 2003. <i>Aids</i> , 2005, 19, 219-220.	1.0	8
162	Severe toxicity associated with the combination of tenofovir and didanosine: case report and review. <i>International Journal of STD and AIDS</i> , 2005, 16, 646-648.	0.5	14

#	ARTICLE	IF	CITATIONS
163	Serum Concentrations of Lipopolysaccharide-Binding Protein as a Biochemical Marker to Differentiate Microbial Etiology in Patients with Community-Acquired Pneumonia. <i>Clinical Chemistry</i> , 2004, 50, 1661-1664.	1.5	14
164	Lipid Abnormalities in HIV-Infected Patients and Lopinavir Plasma Concentrations. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2004, 36, 1107-1109.	0.9	5
165	Didanosine-Associated Toxicity. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2004, 35, 427-428.	0.9	11
166	Single-Slice Computed Tomography and Anthropometric Skinfold Analysis for Evaluation of Facial Lipoatrophy in HIV-Infected Patients. <i>Clinical Infectious Diseases</i> , 2004, 39, 1848-1851.	2.9	16
167	Publication of European Union Research on Infectious Diseases (1991?2001): A Bibliometric Evaluation. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2004, 23, 180-184.	1.3	47
168	Epidemiological and clinical characteristics of occult bacteremia in an adult emergency department in Spain: influence of blood culture results on changes in initial diagnosis and empiric antibiotic treatment. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2004, 23, 881-7.	1.3	28
169	Evaluation of the Immunochromatographic Binax NOW Assay for Detection of <i>Streptococcus pneumoniae</i> Urinary Antigen in a Prospective Study of Community-Acquired Pneumonia in Spain. <i>Clinical Infectious Diseases</i> , 2003, 36, 286-292.	2.9	261
170	Lopinavir Plasma Concentrations and Changes in Lipid Levels During Salvage Therapy with Lopinavir/Ritonavir-Containing Regimens. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2003, 33, 594-600.	0.9	92
171	Fulminant Hepatitis and Fatal Toxic Epidermal Necrolysis (Lyell Disease) Coincident With Clarithromycin Administration in an Alcoholic Patient Receiving Disulfiram Therapy. <i>Archives of Internal Medicine</i> , 2002, 162, 474.	4.3	47
172	Avascular necrosis of the bone in HIV-infected patients: incidence and associated factors. <i>Aids</i> , 2002, 16, 481-483.	1.0	31
173	Acute Pancreatitis as a Complication of Ritonavir Therapy in a Patient with AIDS. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 1998, 17, 810-811.	1.3	31